Plain-English translation of NCT05451043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a blood pressure medication that has been used safely for decades, can help boost the effectiveness of immunotherapy drugs ( and ) in treating advanced pancreatic, liver, or bile duct cancers. Depending on your cancer type, you may also receive chemotherapy alongside the medication. The researchers believe that might help your immune system fight cancer more effectively when combined with these newer immunotherapy treatments.
Standard immunotherapy doesn't work well enough for many patients with these aggressive cancers. Researchers have noticed in laboratory studies that might help the immune system recognize and attack cancer cells better, so this trial is testing whether adding this inexpensive, well-tolerated medication could improve how well the treatment works.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly to receive your treatment. Depending on your cancer type, you will receive (an immunotherapy infusion) every 3–4 weeks, (another immunotherapy drug) on the first day of treatment and possibly later if cancer progresses, and pills taken daily at home. Some patients will also receive chemotherapy infusions on specific days. You will have blood tests and scans to monitor how well the treatment is working and to check for side effects. The study will track you closely throughout your treatment and for some time afterward.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Canada